Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 11/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 10/20 | 0.53 |
| ▸ | TP53 | P04637 | 3/20 | 0.49 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.49 |
| ▸ | PI4KA | P42356 | 5/20 | 0.47 |
| ▸ | PI4K2B | Q8TCG2 | 5/20 | 0.47 |
| ▸ | PI4K2A | Q9BTU6 | 5/20 | 0.47 |
| ▸ | PI4KB | Q9UBF8 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21128128 | 0.78 | ADORA2A (0.46) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL4928331 | 0.76 | TP53 (0.49) | ADORA2AADORA1TP53PI4KAPI4K2B | |
| SCHEMBL13851102 | 0.76 | ADORA2A (0.53) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL21942687 | 0.76 | ADORA2A (0.44) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL13850512 | 0.76 | PI4KA (0.53) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL754966 | 0.76 | ADORA2A (0.53) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL23185942 | 0.74 | ADORA2A (0.47) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL21504439 | 0.73 | PDE8B (0.52) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL24453637 | 0.73 | ADORA2A (0.42) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL21759036 | 0.73 | PDE8B (0.46) | ADORA2AADORA1ADORA2BPI4KAPI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303613-A1 | 3′3′ CYCLIC DINUCLEOTIDES WITH AN ALKENYLENE | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR, V.V.I. (CZ) | 2023-09-28 | — | — | US | disclosed |
| US-11766447-B2 | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2023-09-26 | — | — | US | disclosed |
| EP-4242212-A2 | STING MODULATOR COMPOUNDS WITH SULFAMATE LINKAGES, AND METHODS OF MAKING AND USING | Takeda Pharmaceutical Company Limited (JP) | 2023-09-13 | — | — | EP | disclosed |
| US-20230149560-A1 | LIPID COMPOSITIONS FOR DELIVERY OF STING AGONIST COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20220251135-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | BEONE MEDICINES I GMBH (CH) | 2022-08-11 | — | — | US | disclosed |
| WO-2022127914-A1 | NUCLEOSIDE-THIODIPHOSPHATE-HEPTOSE COMPOUNDS FOR TREATING CONDITIONS ASSOCIATED WITH ALPK1 ACTIVITY | PYROTECH (BEIJING) BIOTECHNOLOGY CO., LTD. (CN) | 2022-06-23 | — | — | WO | disclosed |
| US-20220175811-A1 | STABLE FORMULATIONS OF CYCLIC DINUCLEOTIDE STING AGONIST COMPOUNDS AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. (US) | 2022-06-09 | — | — | US | disclosed |
| US-20220160746-A1 | 3'3'-CYCLIC DINUCLEOTIDE ANALOGUE COMPRISING A CYCLOPENTANYL MODIFIED NUCLEOTIDE AS STING MODULATOR | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I (CZ) | 2022-05-26 | — | — | US | disclosed |
| US-20220152078-A1 | 2'3'-CYCLIC DINUCLEOTIDES AND PRODRUGS THEREOF | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2022-05-19 | — | — | US | disclosed |
| US-20220033431-A1 | Cyclic Di-Nucleotide Compounds as STING Agonists | MERCK SHARP & DOHME CORP. (US) | 2022-02-03 | — | — | US | disclosed |
| US-20100152211-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION | 2010-06-17 | — | — | US | disclosed |
| US-20100104532-A1 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| EP-2174936-A1 | PNA monomer and precursor | Panagene, Inc. (KR) | 2010-04-14 | — | — | EP | disclosed |
| US-20100016252-A1 | Mannich Base N-Oxide Drugs | State of Oregon Acting By and Through The Oregon State Board of Higher Education On Behalf of The U (US) | 2010-01-21 | — | — | US | disclosed |
| EP-1501812-B1 | PNA MONOMER AND PRECURSOR | PANAGENE INC (KR) | 2009-12-30 | — | — | EP | disclosed |
| EP-1470114-B1 | PEPTIDE NUCLEIC ACID OLIGOMERS FROM 1-BENZENESULFONYL-3-AMINO ACID SIDE CHAIN-4-(2-NUCLEOBASE(ACETYL))-PIPERAZIN-2-ONES | PANAGENE INC (KR) | 2009-08-19 | — | — | EP | disclosed |
| US-7411065-B2 | Peptide nucleic acid monomers: diphenylmethyl, benzyl, alkylthioalkyl, or phenylthioalkyl esters of N-(1-[4-(2-benzothiazolyl-, 2-benzoxazolyl-, 2-benzofuranyl- or 2-benzothiophenyl-sulfonyl)-3-piperazinon-1-ylcarbonylmethyl]pyrimidon-4-yl)carbamic acids | PANAGENE, INC. (KR) | 2008-08-12 | — | — | US | disclosed |
| US-7371860-B2 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2008-05-13 | — | — | US | disclosed |
| US-7211668-B2 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2007-05-01 | — | — | US | disclosed |
| US-7179896-B2 | Method of making PNA oligomers | PANAGENE, INC. (KR) | 2007-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149560-A1 | LIPID COMPOSITIONS FOR DELIVERY OF STING AGONIST COMPOUNDS AND USES THEREOF | STING1, CGAS, TLR9 | ADORA2A 2409/4885ADORA1 2287/4885TP53 768/4885 |
| US-20100152211-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PIK3CG | ADORA2A 3432/4885ADORA1 2913/4885TP53 1147/4885 |
| US-20220033431-A1 | Cyclic Di-Nucleotide Compounds as STING Agonists | STING1, CGAS, IFNAR1 | ADORA2A 64/4885ADORA1 32/4885TP53 4380/4885 |
| US-11766447-B2 | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator | STING1, MAVS, CGAS | ADORA2A 660/4885ADORA1 1854/4885TP53 1360/4885 |
| US-20220160746-A1 | 3'3'-CYCLIC DINUCLEOTIDE ANALOGUE COMPRISING A CYCLOPENTANYL MODIFIED NUCLEOTIDE AS STING MODULATOR | STING1, MAVS, CGAS | ADORA2A 652/4885ADORA1 1736/4885TP53 1283/4885 |
| US-20100104532-A1 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | SLC29A1, NUDT1, EIF2AK2 | ADORA2A 545/4885ADORA1 199/4885TP53 3653/4885 |
| US-20220152078-A1 | 2'3'-CYCLIC DINUCLEOTIDES AND PRODRUGS THEREOF | STING1, CGAS, NT5C2 | ADORA2A 121/4885ADORA1 184/4885TP53 385/4885 |
| US-20220251135-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | STING1, CGAS, MAVS | ADORA2A 122/4885ADORA1 209/4885TP53 482/4885 |
| US-20100016252-A1 | Mannich Base N-Oxide Drugs | ASAH2, MAN2B1, NNT | ADORA2A 472/4885ADORA1 625/4885TP53 3970/4885 |
| US-20220175811-A1 | STABLE FORMULATIONS OF CYCLIC DINUCLEOTIDE STING AGONIST COMPOUNDS AND METHODS OF USE THEREOF | STING1, CGAS, IRF3 | ADORA2A 177/4885ADORA1 266/4885TP53 141/4885 |
| US-20230303613-A1 | 3′3′ CYCLIC DINUCLEOTIDES WITH AN ALKENYLENE | STING1, CGAS, IRF3 | ADORA2A 237/4885ADORA1 217/4885TP53 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.